cNew York, Feb 7, 2026, 17:29 EST — Market closed.
- Thermo Fisher closed out Friday at $542.83, holding steady after Thursday’s steep slide.
- Franklin’s manufacturing site in Massachusetts is set to wind down by the end of 2026, with as many as 80 jobs on the line, according to a state notice.
- Jobs and inflation data out of the U.S. next week might shake up rate expectations, sending fresh waves through the life-sciences tools sector.
Thermo Fisher Scientific (TMO.N) finished Friday, Feb. 6, at $542.83, flat following Thursday’s near 4% slide. U.S. markets are closed Saturday. Eyes now turn to Monday for clues on whether the selling has bottomed out.
Shares have been all over the place, with the company straddling a tricky divide: research budgets that can vanish quickly, and steadier demand from drugmakers for services and tools. That tension is coming to a head—where the stock heads next could come down to which side of the company’s business calls the shots.
Macro keeps its grip. The U.S. jobs report lands Feb. 11, with January’s CPI inflation numbers set for Feb. 13, both rescheduled after a brief government services hiccup, according to the Bureau of Labor Statistics calendar.
Thermo Fisher slid 4.04% on Thursday, Feb. 5, lagging behind as stocks sold off across the board. The S&P 500 was down 1.23%, with the Dow losing 1.20% that session, MarketWatch data showed.
Friday saw a sharp shift. The S&P 500 climbed 1.97% and the Dow picked up 2.47%. Thermo Fisher edged up just 0.09%, trailing the broader rally; Danaher (DHR.N) improved by 0.40%, according to MarketWatch.
Thermo Fisher is planning to shut down its Franklin, Massachusetts manufacturing site and cut as many as 80 jobs, a move set to take place between Dec. 31, 2026 and Dec. 31, 2027. That’s according to a report referencing an updated Worker Adjustment and Retraining Notification (WARN) notice—the standard filing employers use to signal significant layoffs or closures.
It’s a while off, yet investors watch plant shifts for signals on demand and margins. Here, even a minor change in footprint gets noticed.
What’s hanging over Thermo Fisher right now? Customer budgets. Back in late January, the company projected 2026 adjusted profit to come in under Wall Street’s target, blaming a pullback in U.S. academic research funding after grant freezes and budget cuts. “Our assumption for academic and government … is similar conditions to last year,” CEO Marc Casper told analysts on the earnings call. He said customer caution would “probably abate as the year goes down.” First-quarter growth? Bernstein analysts labeled it “soft,” according to Reuters. Reuters
Thermo Fisher’s main lines range from lab gear and supplies to services like contract drug development and manufacturing. The first category is tied mostly to universities and government labs, while the second depends more on spending from pharma and biotech companies.
The road’s far from smooth. If research budgets shrink further, or public funding gets rattled, orders could dry up fast—and this stock has already proven it’s capable of tumbling sharply when sentiment sours.
All eyes on next week: Wednesday’s U.S. employment data (Feb. 11) and then Friday’s CPI figures (Feb. 13) could jolt rate forecasts—and with them, the valuation outlook for the big healthcare tools stocks.
